Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents
- 1 December 2015
- journal article
- Published by Elsevier in Neuropharmacology
- Vol. 99, 448-458
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81171193, 30700881)
This publication has 36 references indexed in Scilit:
- A pilot study on the effect of cognitive training on BDNF serum levels in individuals with Parkinson’s diseaseFrontiers in Human Neuroscience, 2015
- Pharmacological Treatment of Parkinson DiseaseJAMA, 2014
- Sustained induction of neuronal addition to the adult rat neostriatum by AAV4-delivered noggin and BDNFGene Therapy, 2011
- Deoxygedunin, a Natural Product with Potent Neurotrophic Activity in MicePLOS ONE, 2010
- A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavoneProceedings of the National Academy of Sciences, 2010
- Design of a Conformationally Defined and Proteolytically Stable Circular Mimetic of Brain-derived Neurotrophic FactorJournal of Biological Chemistry, 2008
- Protocol for the MPTP mouse model of Parkinson's diseaseNature Protocols, 2007
- Trk Receptors: Roles in Neuronal Signal TransductionAnnual Review of Biochemistry, 2003
- Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonismTrends in Neurosciences, 2000
- BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigraNature, 1991